Clinical Trials

Numerous clinical trials evaluate verapamil across cardiovascular, neurological, and inflammatory indications, including hypertension, metabolic syndrome, cluster headache, ischemic stroke, knee osteoarthritis, asthma, and keloids. Ranging from phase 1 through phase 4, these studies involve both academic medical centers, such as Assistance Publique - Hôpitaux de Paris, and commercial sponsors like Abbott and Calosyn Pharma, Inc. Recruitment statuses span actively recruiting, completed, and terminated studies, including trials investigating R-verapamil for episodic cluster headache prophylaxis and ischemic stroke.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07655440 NOT_YET_RECRUITING
Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
Stanford University
 2026-07 PHASE4
NCT07061574 RECRUITING
Type 1 Diabetes; New Onset
City of Hope Medical Center
 2026-03-10 PHASE1; PHASE2
NCT07199946 RECRUITING
Type 1 Diabetes
Johnny Ludvigsson
 2025-08-06 PHASE1; PHASE2
NCT07445789 NOT_YET_RECRUITING
Atrial Fibrillation (AF)
Martini Hospital Groningen
 2026-06 PHASE4
NCT06455319 RECRUITING
Type 1 Diabetes
University of Florida
 2025-11-12 PHASE2
NCT07688070 NOT_YET_RECRUITING
Cystic Fibrosis Related Diabetes; Cystic Fibrosis (CF); Abnormal Glucose Tolerance
Rhode Island Hospital
 2026-08-01 PHASE2
NCT07706075 NOT_YET_RECRUITING
Atrial Fibrillation (AF); Atrial Fibrillation With Rapid Ventricular Response
Muhammad Ali Javed
 2027-01-01 PHASE4
NCT05569382 RECRUITING
Non-obstructive Hypertrophic Cardiomyopathy
Morten Steen Kvistholm Jensen
 2022-08-10 PHASE4
NCT07804849 RECRUITING
Type 1 Diabetes Mellitus
Ain Shams University
 2026-08-20 PHASE2; PHASE3
NCT06483789 SUSPENDED
Panic Disorder; Mental Illness
HB BioTech, LLC
 2024-10-29 PHASE2
NCT06799169 ACTIVE_NOT_RECRUITING
Tinnitus
University of California, Irvine
 2025-06-01 PHASE4
NCT07796191 NOT_YET_RECRUITING
Healthy Adult Participants
Jiangsu vcare pharmaceutical technology co., LTD
 2026-09-20 PHASE1
NCT03347786 RECRUITING
Ischemic Stroke
Global Neurosciences Institute
 2017-04-20 PHASE1; PHASE2
NCT06897969 NOT_YET_RECRUITING
Keloid Scars
Nishtar Medical University
 2025-04-01 PHASE4
NCT04406259 ACTIVE_NOT_RECRUITING
Cluster Headache
Centre Hospitalier Universitaire de Nice
 2020-11-02 PHASE4
NCT05593757 UNKNOWN
Short-coupled Idiopathic Ventricular Fibrillation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
 2022-10-01 PHASE2
NCT03449251 UNKNOWN
Cardiovascular Diseases; Type 2 Diabetes Mellitus
Cambridge University Hospitals NHS Foundation Trust
 2018-03-28 PHASE2
NCT07420166 COMPLETED
Keloid
Muhammad Aamir Latif
 2025-01-01
NCT04545151 COMPLETED
Diabetes Mellitus, Type 1
Medical University of Graz
 2021-02-08 PHASE2
NCT06916897 COMPLETED
Healthy Subjects
Edgewise Therapeutics, Inc.
 2025-01-08 PHASE1
NCT06717685 RECRUITING
Supraventricular Tachycardia (SVtach)
Rashid Latif Medical College
 2024-10-28 PHASE3
NCT06447688 COMPLETED
Radial Artery Spasm
Mersin Medicalpark Hastanesi
 2024-06-05 PHASE4
NCT06847620 COMPLETED
Hand Surgery
Ain Shams University
 2024-03-01 PHASE4
NCT06354556 COMPLETED
Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.
 2024-04-26 PHASE1
NCT05855070 UNKNOWN
Peyronie's Disease; Hyaluronic Acid; Verapamil
Benha University
 2023-05-20
NCT01996436 TERMINATED
Cerebral Vasospasm
Peng Roc Chen, MD
 2016-08-29 PHASE4
NCT06118684 COMPLETED
Chronic Obstructive Pulmonary Disease Exacerbation; COPD
EpiEndo Pharmaceuticals
 2023-10-23 PHASE1
NCT05745337 UNKNOWN
Atrial Fibrillation; Diastolic Dysfunction; HFpEF - Heart Failure With Preserved Ejection Fraction
University of Vermont
 2023-02-06 PHASE1
NCT04404439 COMPLETED
Tinnitus, Subjective; Tinnitus
University of California, Irvine
 2019-09-26 PHASE4
NCT05625503 COMPLETED
Vasospasm;Peripheral; Burning; Pain
University of Illinois at Chicago
 2022-12-13 EARLY_PHASE1
NCT06031454 COMPLETED
Drug Drug Interaction
Guangdong Raynovent Biotech Co., Ltd
 2023-09-01 PHASE1
NCT05399576 UNKNOWN
Coronary Artery Disease
The First Affiliated Hospital of Zhejiang Chinese Medical University
 2022-05-17 PHASE2
NCT05183997 UNKNOWN
Regional Anesthesia Morbidity
Assiut University
 2022-01
NCT04573751 COMPLETED
ST Elevation Myocardial Infarction; Percutaneous Coronary Intervention; No-Reflow Phenomenon
Tomsk National Research Medical Center of the Russian Academy of Sciences
 2020-12-30
NCT03845010 COMPLETED
Ventricular Premature Beats
Maatschap Cardiologie Zwolle
 2019-02-12
NCT05304533 COMPLETED
Healthy Participants
Bristol-Myers Squibb
 2022-04-21 PHASE1
NCT04233034 COMPLETED
Type1 Diabetes
Jaeb Center for Health Research
 2020-07-09 PHASE3
NCT04513509 COMPLETED
Atrial Fibrillation; Rate Control; Cardiopulmonary Exercise Test
National Taiwan University Hospital
 2020-10-21
NCT03013933 COMPLETED
Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
City of Hope Medical Center
 2017-05-03 PHASE1
NCT04790331 UNKNOWN
Verapamil; Diltiazim; FESS
Assiut University
 2021-03-01 EARLY_PHASE1
NCT04356196 UNKNOWN
Endoscopic Sinus Surgery; Heart Rate; Blood Loss
Assiut University
 2021-06-15 EARLY_PHASE1
NCT05847413 COMPLETED
Type 1 Diabetes
Benaroya Research Institute
 2020-05-30 EARLY_PHASE1
NCT04351763 COMPLETED
COVID-19
Nicolaus Copernicus University
 2020-05-20 PHASE2; PHASE3
NCT04203368 COMPLETED
Supraventricular Tachycardia
Ain Shams University
 2020-02-01
NCT03098680 TERMINATED
Drug-Related Side Effects and Adverse Reactions; Cardiovascular System Disease
Cambridge University Hospitals NHS Foundation Trust
 2017-04-24 PHASE1
NCT02912663 COMPLETED
Ischemic Stroke
Justin Fraser
 2017-10-11 PHASE1
NCT04008186 COMPLETED
Healthy Adult Subjects
Biogen
 2019-06-14 PHASE1
NCT03150524 WITHDRAWN
Reversible Cerebral Vasoconstriction Syndrome
Johns Hopkins University
 2017-07-01 PHASE4
NCT03782662 COMPLETED
Respiratory Syncytial Virus Infections
Pfizer
 2018-11-07 PHASE1
NCT02248753 COMPLETED
Atrial Fibrillation
Maastricht University Medical Center
 2014-10
NCT03307252 COMPLETED
Healthy
Boehringer Ingelheim
 2017-10-25 PHASE1
NCT03102190 TERMINATED
Sinusitis; Nasal Polyps
Benjamin Bleier
 2017-06-05 PHASE1
NCT02209155 TERMINATED
Episodic Cluster Headache
Center Laboratories, Inc.
 2013-11 PHASE2
NCT03296800 COMPLETED
Type 2 Diabetes Mellitus
Theracos
 2017-09-27 PHASE1
NCT02372253 COMPLETED
Type 1 Diabetes Mellitus
University of Alabama at Birmingham
 2015-02 PHASE2
NCT02772354 UNKNOWN
Ventricular Arrhythmia
Meshalkin Research Institute of Pathology of Circulation
 2016-04 PHASE2; PHASE3
NCT03070470 COMPLETED
Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
Food and Drug Administration (FDA)
 2017-03-14 PHASE1
NCT02527993 COMPLETED
Hypoglycemia; Obesity; Surgery
Zealand University Hospital
 2015-10 PHASE4
NCT02823106 WITHDRAWN
Ischemic Stroke
Justin Fraser
 2016-08 PHASE1
NCT02454491 COMPLETED
Heart Disease, Ischemic
University Hospital of Ferrara
 2015-05 PHASE4
NCT02653872 COMPLETED
Healthy Subjects
AstraZeneca
 2016-01-22 PHASE1
NCT02235558 COMPLETED
Ischemic Stroke
Justin Fraser
 2013-02-01 PHASE1
NCT02454608 TERMINATED
Sinusitis; Nasal Polyps
Benjamin Bleier
 2015-05
NCT00706810 COMPLETED
Cancer; Brain Cancer; Meningioma
University of Utah
 2007-12 PHASE2
NCT01607073 COMPLETED
Dravet Syndrome
Gillette Children's Specialty Healthcare
 2012-04 PHASE2
NCT02319148 COMPLETED
Healthy Volunteers
Pfizer
 2014-07 PHASE1
NCT01669304 COMPLETED
Vestibular Migraine; Chronic Subjective Dizziness
Mayo Clinic
 2012-08 PHASE1
NCT01675362 COMPLETED
Kidney Calculi
Mansoura University
 2012-08 PHASE4
NCT02144792 UNKNOWN
Epilepsy
Seoul National University Hospital
 2013-05 PHASE2
NCT01720056 TERMINATED
Keloid Scars
The University of Western Australia
 2012-10 PHASE4
NCT02111317 COMPLETED
Healthy Subjects; Pharmacokinetics of ASP015K
Astellas Pharma Global Development, Inc.
 2013-10 PHASE1
NCT01873950 COMPLETED
Drug-induced Surface ECG Changes
Food and Drug Administration (FDA)
 2013-05 PHASE1
NCT01645709 TERMINATED
Osteoarthritis of the Knee
Calosyn Pharma, Inc.
 2012-04 PHASE1; PHASE2
NCT01126307 UNKNOWN
Epilepsy; Seizures
University Health Network, Toronto
 2010-06
NCT00896428 COMPLETED
Asthma
University Hospital, Bordeaux
 2009-12 PHASE2
NCT01437384 COMPLETED
Idiopathic Thrombocytopenic Purpura (ITP)
Eisai Inc.
 2011-09 PHASE1
NCT01655303 COMPLETED
Rapid Ventricular Response Atrial Fibrillation
Tehran University of Medical Sciences
 2011-02 PHASE4
NCT01471704 COMPLETED
Healthy
Bristol-Myers Squibb
 2011-10 PHASE1; PHASE2
NCT01402427 COMPLETED
Coronary Disease; Verapamil Toxicity
State Health Center, Hungary
 2011-03
NCT01655316 COMPLETED
Paroxysmal Supraventricular Tachycardia
Tehran University of Medical Sciences
 2010-10 PHASE4
NCT01276301 COMPLETED
Healthy
Boehringer Ingelheim
 2011-01 PHASE1
NCT01197781 COMPLETED
Drug Drug Interactions; Healthy Volunteers
AstraZeneca
 2010-09 PHASE1
NCT00313157 COMPLETED
Atrial Fibrillation
Asker & Baerum Hospital
 2006-04 PHASE3
NCT00593463 COMPLETED
Drug Dependence
University of Arkansas
 2006-09 PHASE1
NCT01128634 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2010-03-04 PHASE1
NCT01943487 COMPLETED
Drug-Drug Interaction (DDI); Healthy Subjects
Astellas Pharma Europe B.V.
 2009-08 PHASE1
NCT00804895 COMPLETED
Cluster Headache
Assistance Publique - Hôpitaux de Paris
 2008-12 PHASE2; PHASE3
NCT00552565 COMPLETED
Irritable Bowel Syndrome With Diarrhea
AGI Therapeutics, Inc.
 2007-09 PHASE3
NCT00712894 COMPLETED
Acute Myocardial Infarction; Percutaneous Coronary Intervention
Fudan University
 2006-12 PHASE4
NCT00745576 COMPLETED
Alzheimer Disease
Wyeth is now a wholly owned subsidiary of Pfizer
 2008-10 PHASE1
NCT00707551 COMPLETED
Healthy
AstraZeneca
 2008-07 PHASE1
NCT00983242 COMPLETED
Pharmacokinetics
Mutual Pharmaceutical Company, Inc.
 2008-09 PHASE1
NCT02171533 COMPLETED
Healthy
Boehringer Ingelheim
 2008-06 PHASE1
NCT00668967 COMPLETED
Healthy Volunteers
Pfizer
 2008-02 PHASE1
NCT01295047 COMPLETED
Marfan Syndrome
Cardiff University
 2006-07 PHASE4
NCT01467687 COMPLETED
Healthy
Synerx Pharma, LLC
 2007-07 PHASE1
NCT00235001 COMPLETED
Hypertension
Abbott
 2004-06 PHASE4
NCT00234858 COMPLETED
Hypertension; Metabolic Syndrome
Abbott
 2004-03 PHASE4
NCT00648050 COMPLETED
Healthy
Mylan Pharmaceuticals Inc
 2006-03 PHASE1
NCT00649805 COMPLETED
Healthy
Mylan Pharmaceuticals Inc
 2006-01 PHASE1
NCT00647673 COMPLETED
Healthy
Mylan Pharmaceuticals Inc
 2006-01 PHASE1
NCT00235014 COMPLETED
Hypertension; Diabetes
Abbott
 1997-03 PHASE4
NCT00648401 COMPLETED
Healthy
Mylan Pharmaceuticals Inc
 2006-01 PHASE1
NCT00234871 COMPLETED
Hypertension; Diabetes; Proteinuria
Abbott
 2004-01 PHASE4
NCT00679653 COMPLETED
Obesity; Hypertension
Abbott
 2002-02 PHASE3
NCT00348530 UNKNOWN
Systolic Heart Failure; Myocardial Disease; Cardiomyopathy
Medical University of Silesia
 2006-01 PHASE4
NCT00374465 UNKNOWN
Dilated Cardiomyopathy
Medical University of Silesia
 2006-01 PHASE4
NCT00559169 WITHDRAWN
Catamenial Epilepsy
University Health Network, Toronto
 2009-02
NCT00518947 COMPLETED
Mania
University of Pittsburgh
 1994-11 PHASE3
NCT01261286 COMPLETED
Crohn's Disease
University of Alberta
 PHASE1
NCT00000556 COMPLETED
Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
National Heart, Lung, and Blood Institute (NHLBI)
 1995-03 PHASE3
NCT00133692 COMPLETED
Hypertension; Coronary Artery Disease
University of Florida
 1997-09 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-06-17)

Check the Verapamil product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Verapamil binds to L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue, blocking transmembrane calcium influx to impair calcium-dependent excitation-contraction coupling and induce muscle relaxation. This arterial vasodilation and decreased cardiac conduction velocity effectively lower systemic vascular resistance and slow heart rate, providing therapeutic efficacy in clinical conditions such as hypertension, cardiac arrhythmias, and ischemic disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.